JP2016053042A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016053042A5 JP2016053042A5 JP2015203440A JP2015203440A JP2016053042A5 JP 2016053042 A5 JP2016053042 A5 JP 2016053042A5 JP 2015203440 A JP2015203440 A JP 2015203440A JP 2015203440 A JP2015203440 A JP 2015203440A JP 2016053042 A5 JP2016053042 A5 JP 2016053042A5
- Authority
- JP
- Japan
- Prior art keywords
- formula
- compound
- optionally substituted
- hydrogen
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 24
- 229910052739 hydrogen Inorganic materials 0.000 claims 16
- 239000001257 hydrogen Substances 0.000 claims 16
- 125000005415 substituted alkoxy group Chemical group 0.000 claims 11
- 125000000753 cycloalkyl group Chemical group 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 8
- 125000000623 heterocyclic group Chemical group 0.000 claims 7
- 150000002431 hydrogen Chemical group 0.000 claims 7
- 125000003118 aryl group Chemical group 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 5
- 125000003710 aryl alkyl group Chemical group 0.000 claims 5
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims 5
- -1 - alkyl Chemical group 0.000 claims 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 4
- 238000000034 method Methods 0.000 claims 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 2
- 230000002378 acidificating effect Effects 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 2
- 229940127089 cytotoxic agent Drugs 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 1
- ZXOFAHRGRROAQR-UHFFFAOYSA-N 1-(isocyanomethylsulfonyl)-2-methylbenzene Chemical compound CC1=CC=CC=C1S(=O)(=O)C[N+]#[C-] ZXOFAHRGRROAQR-UHFFFAOYSA-N 0.000 claims 1
- CXMXBFQRJAIBDD-UHFFFAOYSA-N 9H-cyclohepta[d]pyrimidine-8-carboxamide Chemical compound N1=CN=CC2=C1CC(=CC=C2)C(=O)N CXMXBFQRJAIBDD-UHFFFAOYSA-N 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical class CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 102000001253 Protein Kinase Human genes 0.000 claims 1
- 230000029936 alkylation Effects 0.000 claims 1
- 238000005804 alkylation reaction Methods 0.000 claims 1
- 238000011319 anticancer therapy Methods 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000008482 dysregulation Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- CNSGSATYYDDERW-UHFFFAOYSA-N n-(2,6-diethylphenyl)-2-[2-methoxy-4-(4-methylpiperazin-1-yl)anilino]-10-methyl-6,7-dihydro-5h-pyrrolo[4,5]cyclohepta[1,2-d]pyrimidine-8-carboxamide Chemical compound CCC1=CC=CC(CC)=C1NC(=O)C1=CN(C)C(C2=N3)=C1CCCC2=CN=C3NC1=CC=C(N2CCN(C)CC2)C=C1OC CNSGSATYYDDERW-UHFFFAOYSA-N 0.000 claims 1
- RSPVCUOYQUFMQA-UHFFFAOYSA-N n-(2,6-diethylphenyl)-2-[2-methoxy-4-(4-pyrrolidin-1-ylpiperidin-1-yl)anilino]-10-methyl-6,7-dihydro-5h-pyrrolo[4,5]cyclohepta[1,2-d]pyrimidine-8-carboxamide Chemical compound CCC1=CC=CC(CC)=C1NC(=O)C1=CN(C)C(C2=N3)=C1CCCC2=CN=C3NC1=CC=C(N2CCC(CC2)N2CCCC2)C=C1OC RSPVCUOYQUFMQA-UHFFFAOYSA-N 0.000 claims 1
- ACLQSKDWSJHJCN-UHFFFAOYSA-N n-(2,6-diethylphenyl)-2-[4-[4-(dimethylamino)piperidin-1-yl]-2-methoxyanilino]-10-methyl-6,7-dihydro-5h-pyrrolo[4,5]cyclohepta[1,2-d]pyrimidine-8-carboxamide Chemical compound CCC1=CC=CC(CC)=C1NC(=O)C1=CN(C)C(C2=N3)=C1CCCC2=CN=C3NC1=CC=C(N2CCC(CC2)N(C)C)C=C1OC ACLQSKDWSJHJCN-UHFFFAOYSA-N 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 108060006633 protein kinase Proteins 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11152190 | 2011-01-26 | ||
| EP11152190.2 | 2011-01-26 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013550833A Division JP5925809B2 (ja) | 2011-01-26 | 2012-01-19 | 三環系ピロロ誘導体、その調製方法およびそのキナーゼ阻害剤としての使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016053042A JP2016053042A (ja) | 2016-04-14 |
| JP2016053042A5 true JP2016053042A5 (enExample) | 2016-08-12 |
| JP6118383B2 JP6118383B2 (ja) | 2017-04-19 |
Family
ID=45562287
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013550833A Active JP5925809B2 (ja) | 2011-01-26 | 2012-01-19 | 三環系ピロロ誘導体、その調製方法およびそのキナーゼ阻害剤としての使用 |
| JP2015203440A Active JP6118383B2 (ja) | 2011-01-26 | 2015-10-15 | 三環系ピロロ誘導体、その調製方法およびそのキナーゼ阻害剤としての使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013550833A Active JP5925809B2 (ja) | 2011-01-26 | 2012-01-19 | 三環系ピロロ誘導体、その調製方法およびそのキナーゼ阻害剤としての使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US8975267B2 (enExample) |
| EP (1) | EP2668190B1 (enExample) |
| JP (2) | JP5925809B2 (enExample) |
| CN (1) | CN103339134B (enExample) |
| BR (1) | BR112013018515B1 (enExample) |
| ES (1) | ES2602791T3 (enExample) |
| RU (1) | RU2591191C2 (enExample) |
| WO (1) | WO2012101032A1 (enExample) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR077468A1 (es) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
| JP5980225B2 (ja) * | 2010-12-17 | 2016-08-31 | ナーヴィアノ メディカル サイエンシズ エス．アール．エル． | キナーゼ阻害剤としての置換ピラゾロ−キナゾリン誘導体 |
| RU2591191C2 (ru) | 2011-01-26 | 2016-07-10 | НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. | Трициклические пирроло производные, способ их получения и их применение в качестве ингибиторов киназы |
| GB201216018D0 (en) | 2012-09-07 | 2012-10-24 | Cancer Rec Tech Ltd | Pharmacologically active compounds |
| GB201216017D0 (en) * | 2012-09-07 | 2012-10-24 | Cancer Rec Tech Ltd | Inhibitor compounds |
| ES2649156T3 (es) | 2013-01-14 | 2018-01-10 | Incyte Holdings Corporation | Compuestos bicíclicos de carboxamida aromática útiles como inhibidores de quinasas Pim |
| CA2897333C (en) | 2013-01-15 | 2021-07-06 | Incyte Corporation | Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors |
| CR20160135A (es) | 2013-08-23 | 2016-08-05 | Incyte Corp | Compuestos de carboxamida de furo y tienopiridina útiles como inhibidores de cinasas pim |
| GB201403536D0 (en) * | 2014-02-28 | 2014-04-16 | Cancer Rec Tech Ltd | Inhibitor compounds |
| EP3125920B1 (en) | 2014-04-04 | 2020-12-23 | Del Mar Pharmaceuticals | Dianhydrogalactitol, diacetyldianhydrogalactitol or dibromodulcitol to treat non-small-cell carcinoma of the lung and ovarian cancer |
| MX368767B (es) * | 2014-04-07 | 2019-10-15 | Netherlands Translational Res Center B V | (5,6-dihidro)pirimido[4,5-e]indolizinas. |
| WO2016010897A1 (en) | 2014-07-14 | 2016-01-21 | Incyte Corporation | Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors |
| US9580418B2 (en) | 2014-07-14 | 2017-02-28 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors |
| JP6993233B2 (ja) | 2015-04-17 | 2022-01-13 | ネザーランズ トランスレーショナル リサーチ センター ビー．ブイ． | Ｔｔｋ阻害剤化学療法の為の予後バイオマーカー |
| ITRM20150212A1 (it) * | 2015-05-15 | 2016-11-15 | Univ Degli Studi Di Palermo | 4,5,6,9-tetraidropirrolo[2',3':3,4] cicloepta[1,2-d] isossazoli, procedimento per la loro produzione e loro uso come antitumorali |
| US9540347B2 (en) | 2015-05-29 | 2017-01-10 | Incyte Corporation | Pyridineamine compounds useful as Pim kinase inhibitors |
| PL3322706T3 (pl) | 2015-07-16 | 2021-07-19 | Array Biopharma, Inc. | Podstawione związki pirazolo[1,5-a]pirydynowe jako inhibitory kinazy ret |
| CN105130980B (zh) * | 2015-09-09 | 2018-05-22 | 沈阳药科大学 | N-3-苯并咪唑噻唑胺类衍生物及其制备方法与应用 |
| TWI734699B (zh) | 2015-09-09 | 2021-08-01 | 美商英塞特公司 | Ｐｉｍ激酶抑制劑之鹽 |
| TW201718546A (zh) | 2015-10-02 | 2017-06-01 | 英塞特公司 | 適用作pim激酶抑制劑之雜環化合物 |
| EP3368039A1 (en) | 2015-10-26 | 2018-09-05 | The Regents of The University of Colorado, A Body Corporate | Point mutations in trk inhibitor-resistant cancer and methods relating to the same |
| RS65987B1 (sr) | 2016-04-04 | 2024-10-31 | Loxo Oncology Inc | Tečne formulacije (s)-n-(5-((r)-2-(2,5-difluorofenil)-pirolidin-1-il)-pirazolo[1,5-]pirimidin-3-il)-3-hidroksipirolidin-1-karboksamida |
| CA3019661A1 (en) | 2016-04-04 | 2017-10-12 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
| US10045991B2 (en) | 2016-04-04 | 2018-08-14 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
| EP3800189B1 (en) | 2016-05-18 | 2023-06-28 | Loxo Oncology, Inc. | Preparation of (s)-n-(5-((r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide |
| JOP20190077A1 (ar) | 2016-10-10 | 2019-04-09 | Array Biopharma Inc | مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret |
| TWI704148B (zh) | 2016-10-10 | 2020-09-11 | 美商亞雷生物製藥股份有限公司 | 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物 |
| JOP20190092A1 (ar) | 2016-10-26 | 2019-04-25 | Array Biopharma Inc | عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها |
| US11168090B2 (en) | 2017-01-18 | 2021-11-09 | Array Biopharma Inc. | Substituted pyrazolo[1,5-a]pyrazines as RET kinase inhibitors |
| WO2018136663A1 (en) | 2017-01-18 | 2018-07-26 | Array Biopharma, Inc. | Ret inhibitors |
| JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
| KR102444482B1 (ko) * | 2017-04-01 | 2022-09-16 | 셍커 파마슈티컬스 (지앙수) 엘티디. | 단백질 인산화효소 억제제로서의 1h-이미다조[4,5-h]퀴나졸린 화합물 |
| GB201709840D0 (en) | 2017-06-20 | 2017-08-02 | Inst Of Cancer Research: Royal Cancer Hospital | Methods and medical uses |
| TWI791053B (zh) | 2017-10-10 | 2023-02-01 | 美商亞雷生物製藥股份有限公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物 |
| TWI876442B (zh) | 2017-10-10 | 2025-03-11 | 美商絡速藥業公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物 |
| WO2019113487A1 (en) | 2017-12-08 | 2019-06-13 | Incyte Corporation | Low dose combination therapy for treatment of myeloproliferative neoplasms |
| EP3740486A1 (en) | 2018-01-18 | 2020-11-25 | Array Biopharma, Inc. | Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors |
| EP3740491A1 (en) | 2018-01-18 | 2020-11-25 | Array Biopharma, Inc. | Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors |
| CA3087578C (en) | 2018-01-18 | 2023-08-08 | Array Biopharma Inc. | Substituted pyrazolo[3,4-d]pyrimidine compounds as ret kinase inhibitors |
| CN117281803A (zh) | 2018-07-31 | 2023-12-26 | 罗索肿瘤学公司 | 喷雾干燥的分散体和制剂 |
| WO2020055672A1 (en) | 2018-09-10 | 2020-03-19 | Array Biopharma Inc. | Fused heterocyclic compounds as ret kinase inhibitors |
| JP2022515197A (ja) | 2018-12-19 | 2022-02-17 | アレイ バイオファーマ インコーポレイテッド | がんを治療するためのｆｇｆｒ阻害剤としての７－（（３，５－ジメトキシフェニル）アミノ）キノキサリン誘導体 |
| EP3898626A1 (en) | 2018-12-19 | 2021-10-27 | Array Biopharma, Inc. | Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases |
| KR102866207B1 (ko) * | 2019-08-02 | 2025-09-29 | 청두 사이노젠 바이오-파마슈티컬 테크놀로지 코., 엘티디. | 단백질 키나제 억제제로 작용하는 1h-[1, 2, 3]트리아졸로[4, 5-h] 퀴나졸린 화합물 |
| US20230101747A1 (en) | 2019-12-06 | 2023-03-30 | Schrödinger, Inc. | Cyclic compounds and methods of using same |
| WO2021134004A1 (en) | 2019-12-27 | 2021-07-01 | Schrodinger, Inc. | Cyclic compounds and methods of using same |
| US20230365584A1 (en) | 2020-09-10 | 2023-11-16 | Schrödinger, Inc. | Heterocyclic pericondensed cdc7 kinase inhibitors for the treatment of cancer |
| CN114685520B (zh) * | 2020-12-25 | 2024-08-30 | 武汉誉祥医药科技有限公司 | 三并环化合物及其药物组合物和应用 |
| WO2022164789A1 (en) | 2021-01-26 | 2022-08-04 | Schrödinger, Inc. | Tricyclic compounds useful in the treatment of cancer, autoimmune and inflammatory disoders |
| TW202300150A (zh) | 2021-03-18 | 2023-01-01 | 美商薛定諤公司 | 環狀化合物及其使用方法 |
| KR20240107329A (ko) * | 2021-12-15 | 2024-07-09 | 신라젠(주) | 신생물성 질환을 치료하는 방법 |
| US20250049926A1 (en) * | 2021-12-15 | 2025-02-13 | Sillajen, Inc. | Pharmaceutical compositions comprising modified betacyclodextrins |
| WO2025059027A1 (en) | 2023-09-11 | 2025-03-20 | Schrödinger, Inc. | Cyclopenta[e]pyrazolo[1,5-a]pyrimidine derivatives as malt1 inhibitors |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL115833A (en) | 1994-11-25 | 1998-10-27 | Zeneca Ltd | 6,6-Dihalo-3,3-dimethyl-5-hydroxy-7,7,7-trifluoroheptanoic acids and their alkyl esters useful as intermediates for insecticides and their preparation |
| MY125533A (en) * | 1999-12-06 | 2006-08-30 | Bristol Myers Squibb Co | Heterocyclic dihydropyrimidine compounds |
| AU2003225580A1 (en) * | 2002-02-19 | 2003-09-09 | Pharmacia Corporation | Tricyclic pyrazole derivatives for the treatment of inflammation |
| KR101084871B1 (ko) * | 2003-05-22 | 2011-11-21 | 네르비아노 메디칼 사이언시스 에스.알.엘. | 피라졸로-퀴나졸린 유도체, 그의 제조 방법 및 상기유도체의 키나제 저해제로서의 용도 |
| CN1897950A (zh) | 2003-10-14 | 2007-01-17 | 惠氏公司 | 稠合芳基和杂芳基衍生物及其使用方法 |
| US8207180B2 (en) * | 2006-11-28 | 2012-06-26 | Nerviano Medical Sciences S.R.L. | Tricyclic indoles and (4,5-dihydro) indoles |
| WO2008067756A1 (fr) | 2006-12-04 | 2008-06-12 | Jiangsu Simcere Pharmaceutical R & D Co., Ltd. | Dérivés de 3-pyrrolo-cyclohexylène-2-dihydro-indolinone et utilisations de ceux-ci |
| PT2125822E (pt) * | 2006-12-21 | 2015-01-30 | Nerviano Medical Sciences Srl | Derivados de pirazol-quinazolina substituídos, processo para sua preparação e seu uso como inibidores da quinase |
| AU2008277676A1 (en) * | 2007-07-16 | 2009-01-22 | Novartis Ag | Heterocyclic compounds useful as MK2 inhibitors |
| US20110052643A1 (en) | 2008-01-07 | 2011-03-03 | Synta Pharmaceuticals Corp. | Compounds for inflammation and immune-related uses |
| WO2009137492A1 (en) * | 2008-05-05 | 2009-11-12 | Abbott Laboratories | Heteroaryl-fused macrocyclic pyrimidine derivatives |
| ES2572360T3 (es) * | 2008-06-26 | 2016-05-31 | Servier Lab | Pirazolo-quinazolinas como moduladores de la actividad de la proteína quinasa |
| WO2010012733A1 (en) * | 2008-07-29 | 2010-02-04 | Nerviano Medical Sciences S.R.L. | Use of a cdk inhibitor for the treatment of glioma |
| ES2964764T3 (es) * | 2008-07-29 | 2024-04-09 | Nerviano Medical Sciences Srl | Combinación terapéutica que comprende un inhibidor de cdk y oxaliplatino |
| WO2010058006A1 (en) * | 2008-11-24 | 2010-05-27 | Nerviano Medical Sciences S.R.L. | Cdk inhibitor for the treatment of mesothelioma |
| JP5650193B2 (ja) * | 2009-03-20 | 2015-01-07 | ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ | 胸腺腫の治療のためのキナーゼ阻害剤の使用 |
| ES2660146T3 (es) * | 2009-04-29 | 2018-03-21 | Nerviano Medical Sciences S.R.L. | Sales del inhibidor de cdk |
| AR076784A1 (es) * | 2009-05-26 | 2011-07-06 | Nerviano Medical Sciences Srl | Combinacion terapeutica que comprende un inhibidor de plk1 y un agente antineoplasico |
| ES2553114T3 (es) * | 2009-07-29 | 2015-12-04 | Nerviano Medical Sciences S.R.L. | Sales de inhibidor de plk |
| US9333205B2 (en) * | 2010-07-30 | 2016-05-10 | Nerviano Medical Sciences S.R.L. | Isoxazolo-quinazolines as modulators of protein kinase activity |
| JP5980225B2 (ja) * | 2010-12-17 | 2016-08-31 | ナーヴィアノ メディカル サイエンシズ エス．アール．エル． | キナーゼ阻害剤としての置換ピラゾロ−キナゾリン誘導体 |
| RU2591191C2 (ru) | 2011-01-26 | 2016-07-10 | НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. | Трициклические пирроло производные, способ их получения и их применение в качестве ингибиторов киназы |
-
2012
- 2012-01-19 RU RU2013139353/04A patent/RU2591191C2/ru active
- 2012-01-19 EP EP12702207.7A patent/EP2668190B1/en active Active
- 2012-01-19 WO PCT/EP2012/050773 patent/WO2012101032A1/en not_active Ceased
- 2012-01-19 US US13/980,168 patent/US8975267B2/en active Active
- 2012-01-19 CN CN201280006541.4A patent/CN103339134B/zh active Active
- 2012-01-19 ES ES12702207.7T patent/ES2602791T3/es active Active
- 2012-01-19 BR BR112013018515-5A patent/BR112013018515B1/pt active IP Right Grant
- 2012-01-19 JP JP2013550833A patent/JP5925809B2/ja active Active
-
2015
- 2015-01-30 US US14/609,534 patent/US9309253B2/en active Active
- 2015-10-15 JP JP2015203440A patent/JP6118383B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016053042A5 (enExample) | ||
| JP2014503567A5 (enExample) | ||
| JP6849711B2 (ja) | Ｋｒａｓ ｇ１２ｃの共有結合性阻害剤 | |
| AU2018360854B2 (en) | Modulators of the integrated stress pathway | |
| AU2018358157B2 (en) | Modulators of the integrated stress pathway | |
| JP6784348B2 (ja) | Ｓｔｉｎｇ作動化合物 | |
| AU2015341913B2 (en) | Pharmaceutical compound | |
| US20240173307A1 (en) | Modulators of the integrated stress pathway | |
| JP6527534B2 (ja) | ヒストンメチルトランスフェラーゼ及びｄｎａメチルトランスフェラーゼの二重阻害剤としての新規化合物 | |
| JP5886411B2 (ja) | 新規のピリミジン誘導体 | |
| RU2013139353A (ru) | Трициклические пирролопроизводные, способ их получения и их применение в качестве ингибиторов киназы | |
| US9550738B2 (en) | Bicyclic compounds as kinases inhibitors | |
| KR20180017013A (ko) | K-Ras 조절제 | |
| AU2018360847A1 (en) | Modulators of the integrated stress pathway | |
| CA2901022A1 (en) | Substituted pyridine compounds as inhibitors of histone demethylases | |
| BR122023006150B1 (pt) | Compostos inibidores de hpk1, seu uso, e composição farmacêutica que os compreende | |
| JP2014503566A5 (enExample) | ||
| CN120699028A (zh) | Nek7激酶的抑制剂 | |
| JP2016501251A (ja) | がんの治療のための新規二環フェニル−ピリジン／ピラジン | |
| KR20200039616A (ko) | 사이클린 의존성 키나아제 cdk9의 신규 인히비터 | |
| US10112945B2 (en) | Fused quinoline compunds as PI3K, mTOR inhibitors | |
| AU2015241022A1 (en) | Inhibitors of histone demethylases | |
| JP2019519512A (ja) | ピリミジン誘導体、その調製方法および医療での使用 | |
| ES2782113T3 (es) | Compuestos de quinolina fusionados como inhibidores de PI3K/mTor | |
| EP4225753B1 (en) | Potent and selective compounds as serotonin 1b receptor modulators |